<?xml version='1.0' encoding='utf-8'?>
<document id="9698296"><sentence text="The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite." /><sentence text="The metabolism of valspodar (PSC 833; PSC), which is developed as a multidrug resistance-reversing agent, was investigated to assess the potential for drug-drug interactions and the pharmacological activity of major metabolites" /><sentence text=" The primary metabolites of PSC produced by human liver microsomes were monohydroxylated, as revealed by LC/MS" /><sentence text=" The major site of hydroxylation was at amino acid 9, resulting in M9, as determined by cochromatography with synthetic M9"><entity charOffset="40-50" id="DDI-PubMed.9698296.s4.e0" text="amino acid" /></sentence><sentence text=" Dihydroxylated and N-demethylated metabolites were also detected" /><sentence text=" PSC metabolism in two human livers exhibited KM values of 1" /><sentence text="3-2" /><sentence text="8 microM" /><sentence text=" The intrinsic clearance was 9-36 ml/min/kg of body weight" /><sentence text=" PSC biotransformation was cytochrome P450 (CYP or P450) 3A dependent, based on chemical inhibition and on metabolism by Chinese hamster ovary cells expressing CYP3A" /><sentence text=" Ketoconazole was a competitive inhibitor (Ki = 0"><entity charOffset="1-13" id="DDI-PubMed.9698296.s11.e0" text="Ketoconazole" /></sentence><sentence text="01-0" /><sentence text="04 microM)" /><sentence text=" The inhibition by 27 compounds, including four antineoplastic agents, corresponded to the inhibitory potentials of these compounds toward CYP3A" /><sentence text=" For vinblastine, paclitaxel, doxorubicin, and etoposide, the IC50 values were 5, 12, 20, and 150 microM, respectively"><entity charOffset="5-16" id="DDI-PubMed.9698296.s15.e0" text="vinblastine" /><entity charOffset="18-28" id="DDI-PubMed.9698296.s15.e1" text="paclitaxel" /><entity charOffset="30-41" id="DDI-PubMed.9698296.s15.e2" text="doxorubicin" /><entity charOffset="47-56" id="DDI-PubMed.9698296.s15.e3" text="etoposide" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e0" e2="DDI-PubMed.9698296.s15.e0" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e0" e2="DDI-PubMed.9698296.s15.e1" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e0" e2="DDI-PubMed.9698296.s15.e2" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e0" e2="DDI-PubMed.9698296.s15.e3" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e1" e2="DDI-PubMed.9698296.s15.e1" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e1" e2="DDI-PubMed.9698296.s15.e2" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e1" e2="DDI-PubMed.9698296.s15.e3" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e2" e2="DDI-PubMed.9698296.s15.e2" /><pair ddi="false" e1="DDI-PubMed.9698296.s15.e2" e2="DDI-PubMed.9698296.s15.e3" /></sentence><sentence text=" M9 was also an inhibitor, with a lower apparent affinity for CYP3A (IC50 = 21 microM), compared with that of PSC" /><sentence text=" M9 was also less active as a multidrug resistance-reversing agent" /><sentence text=" M9 demonstrated low potency in sensitizing resistant cells to paclitaxel and was a poor inhibitor of rhodamine-123 efflux from paclitaxel-resistant cells"><entity charOffset="63-73" id="DDI-PubMed.9698296.s18.e0" text="paclitaxel" /><entity charOffset="128-138" id="DDI-PubMed.9698296.s18.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.9698296.s18.e0" e2="DDI-PubMed.9698296.s18.e0" /><pair ddi="false" e1="DDI-PubMed.9698296.s18.e0" e2="DDI-PubMed.9698296.s18.e1" /></sentence><sentence text=" In addition, compared with PSC, a higher concentration of M9 was needed to compete with the photoaffinity labeling of P-glycoprotein" /><sentence text=" Conversely, PSC inhibited only reactions catalyzed by CYP3A, including cyclosporine A metabolism (IC50 = 6"><entity charOffset="72-86" id="DDI-PubMed.9698296.s20.e0" text="cyclosporine A" /></sentence><sentence text="5 microM) and p-hydroxyphenyl-C3'-paclitaxel formation (Ki = 1"><entity charOffset="14-44" id="DDI-PubMed.9698296.s21.e0" text="p-hydroxyphenyl-C3'-paclitaxel" /></sentence><sentence text="2 microM)" /><sentence text=" Thus, PSC behaves in a manner very similar to that of other cyclosporines, and a comparable drug-drug interaction profile is expected"><entity charOffset="61-74" id="DDI-PubMed.9698296.s23.e0" text="cyclosporines" /></sentence><sentence text="" /></document>